JNJ - Johnson & Johnson
Bristol-Myers Squibb offers a deep focus on oncology and hematology with a favorable valuation. Johnson & Johnson provides a diversified mix of innovative medicine and a massive medical technology division.
Operational sales grew 6% in the third quarter of 2026. Full-year operational sales guidance increased to $100.7 billion at the midpoint.
When tech stocks crack, most investors discover too late that their portfolios were far more concentrated than they realized.
Today we highlight a study that found benefits of wearable glucose monitoring devices for all patients with diabetes, regardless of insulin dependence. We also report on a positive trial of a J&J pill in ulcerative colitis, and a discovery about ovaries after menopause.
Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
A dividend that keeps growing beats a fat yield that gets cut, but only if the company can actually afford to keep raising it.
Cliftonlarsonallen Wealth Advisors LLC boosted its stake in Johnson and Johnson (NYSE: JNJ) by 23.5% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 39,674 shares of the company's stock after acquiring an additional 7,547 shares during the period. Cliftonlarsonallen Wealth Advisors LLC's
China pricing and European budget cuts were cited among the pressures behind a MedTech consensus miss that sent Johnson & Johnson shares lower. JNJ investors with losses can request a review.
Johnson & Johnson (NYSE:JNJ) on Tuesday reported upbeat third-quarter results and raised its full-year guidance.
Most investors chase the highest yield they can find, but that single decision quietly destroys the income they worked to build. A three-bucket approach solves a tension most dividend strategies ignore entirely.
Trading in Johnson & Johnson (NYSE:JNJ) is quiet Wednesday. The shares dropped by almost 6% yesterday after the company reported its earnings.
Johnson & Johnson raises its 2026 sales and earnings outlook as strong pharmaceutical growth offsets MedTech challenges, while 2027 dilution clouds the outlook.
Johnson and Johnson crushed earnings, raised guidance, and still watched its stock crater nearly 6% in a single session. Understanding what spooked investors reveals whether Tuesday's selloff is a trap or a warning.
Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway.
Perpetual Ltd lowered its position in shares of Johnson and Johnson (NYSE: JNJ) by 21.4% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 18,795 shares of the company's stock after selling 5,122 shares during the quarter. Perpetual Ltd's holdings in
Johnson & Johnson executive vice president and CFO Joe Wolk discusses the company's third-quarter earnings, raising its full-year guidance, a potential spinoff of its DePuy Synthes orthopedics unit, and more, on 'The Claman Countdown.' #fox #foxbusiness #media #breakingnews #us #usa #new #news #breaking #theclamancountdown #claman #johnsonandjohnson #business #finance #financial #stocks #stockmarket #wallstreet #investing #investment #earnings #corporate #healthcare #health #medical #orthopedics #medicaldevices #depuy #spinoff #revenue #profits #guidance #economy #market #leadership #innovation #pharmaceuticals
Healthcare giants UnitedHealth Group and Johnson & Johnson reported Q3 results on Tuesday, with both raising their full-year earnings outlooks but delivering contrasting reports.
Johnson & Johnson raised its full-year forecast again on October 13, 2026, and CFO Joe Wolk tells Yahoo Finance's Julie Hyman that pharmaceuticals led the way, with oncology up 17% and immunology returning to growth despite losing exclusivity on Stelara. Wolk explains why MedTech growth of about 2.5% needs to improve, how a new heart pump study and Middle East budgets factor in, and why prescriptions for J&J's new oral psoriasis pill are reaching beyond dermatologists.
Most people reach for the 4% rule when they picture retiring at 56 on nearly $6,000 a month, but that rule answers a completely different question than a dividend portfolio does, and the gap between the two changes everything about which accounts you use and whether you can even touch the money.
Johnson & Johnson delivered resilient sales growth and a beat-and-raise quarter, but profitability softness and regulatory risks warrant caution. Innovative Medicine segment shows promise with positive late-stage trial data, while MedTech's OTTAVA system could drive future growth. Despite operational strength, Johnson & Johnson's forward P/E and PEG ratios are at significant premiums, making current valuation unattractive for new accumulation.